Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
Pharmaceutical Investing Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131
Pharmaceutical Investing FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma
Pharmaceutical Investing Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
Pharmaceutical Investing Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
Pharmaceutical Investing Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma
